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According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management.
The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a personalized
approach, which aims at matching the appropriate therapy with the different asthma phenotypes. Traditional asthma phenotypes
have been decomposing by an increasing number of asthma subclasses based on functional and physiopathological mechanisms.
This is possible thanks to the development and application of different omics technologies. The new asthma classification patterns,
particularly concerning severe asthma, include an increasing number of endotypes that have been identified using new omics
technologies.The identification of endotypes provides new opportunities for themanagement of asthma symptoms, but this implies
that biological therapieswhich target inflammatorymediators in the frameof specific patterns of inflammation should be developed.
However, the pathway leading to a precision approach in asthma treatment is still at its beginning.The aimof this review is providing
a synthetic overview of the current asthma management, with a particular focus on severe asthma, in the light of phenotype and
endotype approach, and summarizing the current knowledge about “omics” science and their therapeutic relevance in the field of
bronchial asthma.
1. Introduction
Severe asthmamanagement still represents amatter of debate,
due to asthma heterogeneity and complexity. Today, asthma
is classified and assessed according to both phenotypes and
endotypes approaches. The last reflects the complex interac-
tion of inflammatory molecules and multiple pathways and
systems that are involved in the pathogenesis of asthma. The
use of omics technologies represents an effective way for
better exploring and defining asthma endotypes. More in
general, the omics approach and the application of systems
biology methods provide unbiased tools allowing for better
understanding of asthma pathophysiology and for develop-
ing “precision medicine” approaches. In contrast with the
more general but still used “one size fits all” approach, pre-
cision medicine consider a specifically targeted therapy that
includes specific biological profiles together with patient’s
exposure and lifestyle. The omics technologies are contribut-
ing to the identification of new biomarkers that compose
these biological profiles and consequently to the development
of targeted biological therapies. For a decade, omalizumab
has been the only available therapy for severe allergic asthma.
Recently, new promising drugs such as mepolizumab and
reslizumab have been introduced as a targeted treatment
option for Eosinophilic asthma.
The aim of this review is to offer an overview regarding
themanagement of asthma, fromphenotype to inflammatory
endotypes. We will focus on pathophysiology mechanisms
of severe asthma and on new treatment options based on
different endotypes.Wewill finally discuss the current knowl-
edge about “omics” science and its relevance in exploring new
biological endotypes, which will represent the basis for the
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development of new promising asthma therapies. The tran-
sition from new biomarkers discovery and understanding
and the development of new successful therapies is still very
difficult. Our review will help the clinician to understand
how it will be possible to improve the management of severe
asthma thanks to the most advanced research tools and what
to do to optimize what is already available.
1.1. DataCollection Strategy. For this review, a highly sensitive
search strategy has been developed, and validated keywords
filters have been applied to retrieve articles pertaining to
severe asthma definition and management.
In particular a selective search on PubMed and Medline
was carried out, and research papers, international guide-
lines, recommendations, position papers, systematic reviews,
and Cochrane meta-analyses relevant to the topic have been
included in the review.
We applied a search strategy for identifying the following
keywords.
Keywords for part 1 are as follows: asthma phenotypes,
asthma endotypes, T2-low and T2-high subtypes, targeted
therapies and bronchial thermoplasty coupled with severe
asthma.
Keywords forpart 2 are as follows: genomics, pharmacoge-
nomics, transcriptomics, epigenomics, proteomics andmeta-
bolomics coupled with severe asthma
To retrieve international and European large-scale pro-
jects hand searches were performed of the reference lists of
all pertinent reviews and studies examined. Abstracts from
relevant conferences were searched.
2. External Phenotypes and Endotypes
A phenotype is defined as the set of an organism's observ-
able characteristics or traits, such as its morphology and
development. As a basic definition, the phenotype is mainly
influenced by the interactions between genomic asset and the
influence of several environmental factors. At a molecular
level, the phenotype is the outcome of the expression and
interaction of different endotypes, which are defined by a
distinct functional or pathophysiological mechanism [1].
External Phenotypes of Asthma. Asthma symptoms are tra-
ditionally defined by shortness of breath, wheeze, chest
tightness, and cough. However, it is well known that there are
different asthma phenotypes. Historically, bronchial asthma
was classified as allergic (extrinsic) or nonallergic (intrinsic).
Extrinsic atopic asthma generally develops under the age of
40, and it is triggered by inhaled allergens and is usually
associated with other allergic diseases, such as rhinitis and
dermatitis [2]. On the other hand, intrinsic asthma typically
develops later in life (>40 years old) and is usually less recog-
nizable. By definition, intrinsic asthma is not associated with
allergic sensitization, but aspirin-intolerance often triggers
disease exacerbations. Nowadays, asthma phenotyping also
includes several clinical information such as age, concomi-
tant comorbidities (obesity, allergic rhinitis, and sinusitis),
exacerbations factors (exercise, allergens, and infections), and
response to the treatment.
Endotypes. An endotype is specifically defined by the patho-
physiologic mechanisms underlying the phenotype(s). The
management of severe asthma is benefitting from the char-
acterization of an increasing number of different endotypes,
which represent the targets of specific therapies [3].
3. T2 Subtypes
Asthma phenotyping based on inflammatory cell count
(Eosinophilic, Neutrophilic, and Paucigranulocytic) in tissue
and blood is gaining an increasing interest. Nowadays, two
main subtypes of type 2 inflammation have been defined: T2-
high (T helper type 2 cell high) and T2-low (T helper type 2
cell low) [4, 5].
The T2-high subtype is characterized by the presence of
high eosinophil level in airways and includes the following:
1. early onset, allergic sensitization, responsiveness to inhaled
corticosteroids (ICS); 2. late-onset, absence of allergic sensiti-
zations, sinusitis, and lack of ICS responsiveness; 3. exercised-
induced asthma.
The T2-low subtype is characterized by Neutrophilic or
Paucigranulocytic airway inflammation and may consist of
the following: 1. obesity-related asthma, late-onset; 2. asthma
and chronic obstructive pulmonary disease overlap syn-
drome (ACO)/Neutrophilic, late-onset; 3. smoking-related
asthma; 4. paucigranulocytic, associated with smoothmuscle
(Figure 1) [4].
4. T2-High
4.1. Pathogenesis and Potential Biomarkers. Most of the new
biologic drugs target the Th2 cytokines pathway. These
cytokines (IL-3, IL-4, IL-5, IL-9, and IL-13) are expressed
in bronchial submucosa and could trigger the release of
mediators that could support other inflammation patterns
as well, such as thymic stromal lymphopoietin [6]. Type 2-
high asthma involves different important inflammatory cells
including type 2 innate lymphoid cells, Th2 cells, natural
killer T cells, and mast cells. Cytokines contribute to the
activation and recruitment of immunoglobulin (Ig) E anti-
body-producing B-cells, which sustain the allergic airway
inflammation. Recently, McKenzie and colleagues described
group 2 lymphoid cells producing these cytokines, defining
another pathway which contributes to the T2 high profiling
(Figure 1) [7]. At present, several biomarkers can identify
inflammatory characteristics of T2-high endotypes (serum
IgE, serum periostin, blood eosinophil, and exhaled nitric
oxide eNO) both for adult and in children asthma (Table 1)
[8]. However, the most validated method to assess airway
inflammation is currently the sputum cytometry. At present,
four inflammatory patterns can be defined based on the
granulocytes detected in the sputum: 1. Eosinophilic, 2.
Neutrophilic, 3. Mixed-granulocytic (both neutrophils and
eosinophils are elevated), and 4. Paucigranulocytic (neither
neutrophils nor eosinophils are elevated).
According to several studies, Eosinophilic asthma is
defined by the presence of elevated sputum eosinophil
count (>3% with or without degranulation) and/or blood
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Figure 1: T2-high and T2-low asthma pathway.The T2-high subtype is characterized by the presences of high level of eosinophils in airways,
and the T2-low subtype is characterized by Neutrophilic or Paucigranulocytic airway inflammation. APC antigen presenting cell, ILC2 type
2 innate lymphoid cells, TSLP thymic stromal lymphopoietin, and TNF (tumor necrosis factor).
eosinophil count (≥400 cells/𝜇L) detected at least in two con-
secutive controls and by symptoms and exacerbations control
obtained with treatment aimed at suppressing eosinophils
[9]. However, for the other three patterns, there is no indica-
tion of minimum thresholds.
4.2. TargetedTherapy. In recent years, the therapeutic options
that target the T2-high subtype have been significantly
increasing. At present, the best biomarker predicting a good
response to anti-IL-5, anti-IgE, anti-IL-4/IL-13, corticos-
teroids, and receptor for prostaglandin D
2
(CRTH2) is the
blood eosinophils count, while periostin and dipeptidyl pep-
tidase-4 (DDP-4) can predict response to anti-IL-13 [5].
IgE Blockers. Omalizumab, the first biological approved
for asthma, is a humanized monoclonal antibody (mAb),
approved in 2003 by US Food and Drug Administration
(FDA). It depletes IgE antibodies and blocks their action
on effector cells, by reducing the density of high-affinity
IgE receptors [10]. Omalizumab is effective in patients aged
6–75 years with allergic asthma and sensitized to perennial
allergens and present levels of IgE serum ≥30UI/mL≤1500
UI/m. Omalizumab showed efficacy and safety in random-
ized clinical trials (RCTs) and real-life setting, in terms of
reduction of exacerbation rates and steroid-sparing effect [11].
Furthermore, it indirectly decreases airway eosinophilia and
for this reason it is more effective in patients with higher
levels of exhaled oxide nitric, blood eosinophils, or blood
periostin [11, 12]. These combined biomarkers also showed
a predictive value for clinical response, and discontinuation
of anti-IgE treatment in patients with these features demon-
strated a more rapid loss of asthma control [13]. Severa
studies confirm that a long-term treatment with omalizumab
allows an improvement of symptom control and a sustained
reduction of exacerbation risk in adult patients. [13, 14]. On
the opposite, there is still a lack of biomarkers that can guide
the clinician in continuing or suspending treatment with
patient growth in pediatric populations. However, Baena-
Cagnani and coworkers showed that omalizumab may have
a disease-modifying effect in children with moderate/severe
uncontrolled asthma. During the first 3 years of follow-up,
after the treatment with this drug, they were completely free
of asthma symptoms [15].
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Quilizumab, a humanized IgG1 mAb, targets the M1-
prime segment of membrane-expressed IgE causing the
depletion of IgE-switched and memory B-cells. Unfortu-
nately, clinical studies did not confirm a significant clinical
efficacy in patients with uncontrolled refractory allergic
asthma [16]. Ligelizumab (QGE031), an IgG1k anti-IgE mAb,
has a major suppressor effect on free IgE compared with the
gold standard omalizumab, with a better pharmacodynamic
effect in allergic subjects, even in the case of higher IgE levels.
These improvements could allow a successful treatment in pa-
tients who show inadequate response or unresponsiveness to
omalizumab [17].
Anti-IL-5. Mepolizumab and reslizumab are two mAbs that
bind IL-5 with high specificity and affinity and have been
recently approved for the treatment of severe uncontrolled
Eosinophilic asthma. Mepolizumab is a N-glycosylated IgG1/
k humanized mAb, approved as an add-on subcutaneous
therapy in patients aged at least 18 years with severe
Eosinophilic asthma and blood eosinophil levels of 300 cells/
mcL or greater and 150 cells/mcL during the previous 12
months [18]. Mepolizumab showed efficacy in the reduction
of exacerbations, it exerts an oral glucocorticoid-sparing
effect, and it determines the improvement of quality of life.
However, data on the increase of Forced Expiratory Volume
in 1 Second (FEV1) were contradictory except in theMUSCA
study [19]. Reslizumab, an IgG4/kmAb, has been approved as
an add-on intravenous monthly treatment in patients aged at
least 18 years with severe Eosinophilic asthma, with baseline
blood eosinophilia ≥400 cells/𝜇L [20]. It improves asthma
control, FEV
1
, and quality of life (QoL) [21, 22]. However,
there are still concerns about the route of administration and
the real positioning of this drug in the general context.
Benralizumab, an anti-eosinophil mAb approved in 2017
by FDA, is an IgG1/k antagonist of the 𝛼 chain of human
IL-5 receptor [23, 24]. This drug is the only one that can
induce apoptosis by means of cellular toxicity mechanisms
(antibody-dependent cell-mediated cytotoxicity or ADCC)
in its target cells, reducing the level of eosinophils in tissues by
90–100. Furthermore, its clinical effect is independent of the
IL-5 circulating levels, which usually tends to increase during
asthma exacerbations [25]. Data from RCTs confirmed the
efficacy of benralizumab in reducing annual exacerbations
rates and improving FEV1. Moreover, benralizumab showed
a significant systemic steroid-sparing effect [26, 27].
Anti-IL-4, AntiIL-13. Dupilumab, a fully humanized mAb
anti-IL-4 receptor currently investigated in phase 3 studies,
inhibits the biologic effect of both IL-4 and IL-13 by prevent-
ing their interaction with IL-4 receptor 𝛼 subunit. Several
studies have demonstrated its efficacy in the reduction of
asthma exacerbations and improvement of symptoms, QoL,
and respiratory function [28, 29] irrespective of their baseline
blood Eosinophilic count. There are still doubts about its
safety profile, in particular regarding the evident rise of blood
eosinophil levels which happens predominantly in patients
with asthma and elevated baseline serum eosinophilia [30].
Antibodies targeting free circulating IL-4 (pascolizumab,
altrakincept) [31, 32] or IL-13 (anrukinzumab, IMA-026,
GSK679586) have been studied and appear safe and tolerable,
but they have been discontinued due to failure in reaching
primary outcomes [33–35].
Lebrikizumab and tralokinumab, two IgG4 anti-IL-13
mAb binding free-IL-13, are still under development but, so
far, did not show any clinical improvement in asthma exac-
erbation rate and only a modest clinical effect has been de-
monstrated [36, 37].
Novel Therapies. Several other drugs are currently under
development, including antithymic stromal lymphopoietin
(TSLP) such as AMG157-tezepelumab [38] that mitigates the
early and the late-onset-phase responses to allergens. TSLP,
IL-33, and IL-25 are key mediators of type-2 inflammation
diseases (such as asthma, nasal polyposis, and Eosinophilic
esophagitis); therefore they are deserving an increasing inter-
est as potential target of new drugs. IL-25 and L-33 inhibitors
have unfortunately not reached the clinical outcomes [39].
The stimulation of prostaglandin antagonist’s receptor
(CRTH2), present on lymphocytes, eosinophils, and baso-
phils surface, induces chemotaxis of these inflammatory cells
and the release of mediators. There is a growing interest in
exploring drugs targeting this receptor (fevipiprant, setip-
iprant, and OC000459) and some results are emerging, such
as the improvement in FEV
1
demonstrated by Pettipher et al.
when a specific CRTH2 antagonist was used for patients with
eosinophils count > 250 cells/𝜇L [40, 41].
New interest is emerging around interferon, as it is well
known that respiratory viruses, especially rhinovirus, are
implicated, not only in asthma exacerbations but also in the
pathogenesis of asthma and Th2 inflammation. A phase 2
RCT with IFN-𝛽 treatment has been shown to be effective
in enhancing innate immunity both systemically and in the
lung (it has been demonstrated by serum concentration of
CXCL10 as well as through the improvement of morning
peak-expiratory flow (PEF)) in severe asthmatic patients [42].
The nebulized IFN-𝛽 treatment seems to act on the viral-
response pathway and, administrated at the early onset of cold
symptoms, prevents worsening of asthma symptoms.
T2-high blockers are responsible for clinical benefit in
many patients with T2-high asthma but this may cause recur-
rence of the symptoms [43], so that a true immunomodula-
tion has not yet been demonstrated. However, there is still the
need of further studies that involve larger group of patients
to detect and evaluate new endotypes, particularly for pa-
tients that are unresponsive to the treatments so far avail-
able.
The modern medicine is increasingly moving towards
precision therapy, because it is unlikely that one therapeutic
approach will be able to offer clinical benefit to all T2-high
asthmatic patients. Clinical trials will benefit from a careful
assessment of the targeted pathway and this should be reached
by means of molecular phenotyping approach.
5. T2-Low
5.1. Inflammatory Mechanisms. Neutrophilic asthma is char-
acterized by elevated neutrophils (≥64%), but not eosinophils
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(<3%), by increased total cell count (≥9.7 million cells/g)
detected at least two times, and by unresponsiveness to treat-
ments suppressing eosinophils.
Mixed-granulocytic asthma is identified when there is
evidence of both neutrophils and eosinophils on at least two
detections, independently or concurrently.
Paucigranulocytic asthma has low eosinophils (<3%) and
lowneutrophils (<64%). In that case treatments aimed at sup-
pressing both inflammatory patterns are ineffective in con-
trolling symptoms [3]. On the basis of inflammatory mech-
anisms, two different patterns can be identified: Th1 and
Th17.Th1 cells release IFN𝛾, which is involved in intracellular
infections and autoimmunity.Th17 cells are CD4+ T lympho-
cytes expressing IL-17A, IL-17E, IL-17F, and IL-22, which can
activate neutrophils through the production of IL-8 (Figure 1)
[44]. Airway damage associated with Neutrophilic inflam-
mation leads to mucus gland hyperplasia and hypersecre-
tion, airway hyperreactivity, remodelling, and corticosteroid
insensitivity [45].
Regarding airway remodelling, it can be considered as a
result of an impairedmucosal repair process, characterized by
increased airway smooth muscle mass, subepithelial fibrosis,
and increased number of mucous glands and goblet cells
caused by Th2 cytokines as well as by growth factors and
cytokines produced by epithelial cells and macrophages.
These structural modifications alter airway mechanism and
contribute to airway hyperresponsiveness [44].
5.2. Pathogenesis and Treatment Options. T2-low field rep-
resents a new evolving research area, and to date there are
no effective therapies.This endotype is characterized by non-
Eosinophilic airway inflammation. It occurs in nearly 50%
of patients with asthma [46, 47]. T2-low can be subdivided
into Neutrophilic, characterized by mediators implicated in
the pathogenesis of Neutrophilic inflammation, such as IL-8,
IL-23, and IL-17, and Paucigranulocytic inflammation. These
patients show not optimal response to corticosteroids, but
they have demonstrated good responsiveness to a group of
antibiotics, macrolides (azithromycin and clarithromycin).
The Neutrophilic inflammation in asthma may be due to
corticosteroids treatment inducing impaired apoptosis of
neutrophils and Th17-mediated Neutrophilic inflammation,
pulmonary infections, smoking habit or occupational expo-
sition, and altered airway microbiome [48].
Therapies for non-Eosinophilic inflammation may in-
clude macrolides, statins, and theophylline but data are still
controversial [49, 50].
Other novel small molecules targeting Neutrophilic in-
flammation were investigated, such as C-X-C-chemokine
receptor (CXCR2) antagonists, CXCL8 (IL-8), and perox-
isome proliferator-activated receptor-𝛾 (PPAR𝛾) [51]. Pub-
lished results are contradictory [52, 53].
As for themonoclonal antibodies brodalumab and secuk-
inumab (both anti-IL-17A), no improving in asthma symp-
toms has been shown [54] and daclizumab (anti-CD-25) is
effective in improving symptoms and function, but it is un-
clear to which patients it should be addressed [55]. Studies
that investigated TNF𝛼 blockers (etanercept, golimumab)
did not demonstrate a significant clinical effect in treated
patients [56, 57]. Some other chemokines could be targeted,
including IL-1𝛽 or IL-6 [58] FLAP (5-lipoxygenase-activating
protein) inhibitors such as GSK-2190915, which prevents the
formation of LTB4 [59], involved in response to allergen. No
active clinical trial is currently in development.
Phosphodiesterase (PDE) andProteinKinase Inhibitors. PDE4
inhibitors and dual PDE3 and PDE4 inhibitors exert im-
mune-modulatory effect potentially effective on asthma in-
flammation. RPL554 is a molecule registered in a clinical trial
for the treatment of asthma and COPD [60]. Proteins kinases
are involved in the cellular pathway of proinflammatory
cytokines. Different molecules are under development [61],
including PIK3 kinase inhibitors. PIK3 inhibition partially
shares the mechanisms of action of low dose of theophylline
[62] and some studies have demonstrated a potential effect in
restoring corticosteroid sensitivity [63].
There are no active phase 3 clinical trials for the target
molecules of the T2-low type. It seems that the knowledge
on the pathophysiology of this endotype is still poor and no
treatments are currently available. Understanding the biology
and the pathophysiology of the disease will require a closer
collaboration between clinical specialists and biologists, in a
multidisciplinary effort.
6. Bronchial Thermoplasty
Bronchial thermoplasty (BT) is a nonpharmacological endo-
scopic procedure based on controlled heat release.The poten-
tial effect is an appreciable change in airway wall structure,
by reducing the amount of smooth muscle with a device
called AlairCatheter (Boston Scientific, Natick, MA, USA).
BT is delivered in 3 short sessions, and no incisions or full
anaesthesia is necessary. Each session is routinely performed
under deep sedation administered by an anaesthesiologist
and typically it takes 30–40 minutes to be completed. The
procedure consists in the treatment of right lower lobe, left
lower lobe, and right and left upper lobe in three different
sessions. Sessions are performed every three or four weeks.
BT was approved by FDA in 2010 and according to last
ERS/ATS guidelines it is recommended in adults with severe
refractory asthma after approval by an Institutional Review
Board [64]. The mechanism of action remains unclear. The
literature reports reduction of ASM as a BT target [65].
Recently our team demonstrated a reduction of nerve fibers
in epithelium and ASM.This result could explain the clinical
improvement of patient that underwent BT [66].
Today literature addressing BT treatment of the T2-low
endotype characterized by Neutrophilic or Paucigranulocytic
airway inflammation is poor [3]. In our experience, patients
were included into BT pathway first in the context of a clinical
trial and subsequently as a clinical practice procedure.
Patients were also enrolled for BT treatment when not
responsive to mAbs. Moreover, BT may be considered as
a preferential treatment for patients who could not be
addressed to other therapies, or who decided to perform a
once-in-a-lifetime therapy [67]. On the basis of our experi-
ences and clinical data, BT shows long-term effectiveness [68]
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and, therefore, it should be considered not only an experi-
mental procedure but rather an important treatment option
for adult patients with severe asthma [69].
7. Biomarker Discovery: Through the Detection
of Novel Endotypes
Omics are a neologism that defines a new “global” molecular
biology point of view that through a single analysis can
characterize large-scale members of biochemical pathways
andmolecular functional activities. FromDNAmicroarray to
Next Generation Sequencing (NGS), the omics sciences are
increasing, and they involve new techniques and approaches
in order to better understand the disease and therefore
enabling more effective drugs and therapies [70].
Omics technology is providing new biomarkers that may
be used as novel targets for diagnostic tests and pharmaco-
logic treatments. This will happen through the increasing of
the knowledge of biological mechanisms and the microenvi-
ronment of asthma inflammation. This path is moving for-
ward to the development of “precision medicine” approaches
[70, 71].
Omics are contributing to help precision medicine to
identify the right therapy to the proper clinical phenotype.
The added value of omics technologies is particularly evident
in severe asthma studies aimed at identifying novel endo-
types.
Suffix “ome” derives from “chromosome” and today in-
cludes genomics, transcriptomics, proteomics,metabolomics,
and epigenomics (Figure 2).
Genomics is a branch of genetics that studies the sequenc-
ing and analysis of an organism's genome.
Transcriptomics is the study of complete set of RNA
transcripts that are produced by the genome.
Proteomics refers to the systematic identification and
quantification of the complete complement of proteins (the
proteome) of a biological system (cell, tissue, organ, biological
fluid, or organism).
Metabolomics concerns the scientific study and analysis of
the metabolites produced by a cell, a tissue, or an organism.
Epigenomics is the study of all of the epigenetic changes
in a cell [72].
8. Large-Scale Projects and
the Development of Databases
Todate several international projects that involve hundreds of
adult and children asthmatic patients have been developing
in several countries, in order to better understand severe
asthma, determine differences among asthma patients, and
gain new finding to create new therapeutics options.
One example of these projects is the Severe Asthma
Research Program (SARP), supported by the NIH (National
Heart, Lung and Blood Institute) in the United States. This
program is a network enrolling over 700 patients both adults
and children coming from several states [73].
Another example is the “Unbiased Biomarkers for the
Prediction of RespiratoryDiseaseOutcomes” (U-BIOPRED).
This is a European project involving 16 centers in 11 European
countries. The goal of this large-scale dataset is to increase
the numbers and types of asthma biomarkers by integrating
clinical data with inflammatory biomarkers derived from
omics. U-BIOPRED provided an unbiased algorithm that
trough system biology technology matches an exponential
quantity of data that will enable phenotyping severe asthma
and will pave the way to new tailored therapeutic approach
[74, 75].
Within the European Union, national databases have
been starting to develop. For example, Italian researchers
have recently created the Severe Asthma Network in Italy
(SANI). It is a multicenter register, which involves referral
centers for the treatment of severe asthma. Up to now 549
adults and children patients with different types of asthma
have been included [76, 77]. The aim of this registry is to
identify and characterize patients eligible for biological treat-
ments (biomarkers evaluation and causal-endotype identifi-
cation), to evaluate cost/benefit optimization in the field of
new and traditional treatments, and to investigate treatment
adherence and its determinants. SANI Network provides
the opportunity to create international collaborations with
networks of clinical researchers, in the respiratory field, in
the framework of the SHARP program (Severe Heterogenous
Asthma Research Collaboration, Patient Centers) or ISAR
(International Severe Asthma Registry) [78].
Many other countries have activated severe asthma reg-
istries, such as United Kingdom, Belgium, Germany, and
Australia. These initiatives are providing a huge amount of
information for large-scale experiments, with the hope that
this data will be freely accessible [79–82].
9. Genomics of Asthma
Different genes have been associated with asthma severity.
Genome-wide association studies (GWASs) contributed to
identifying several asthma risk loci. To date, several studies
have been performed trying to link the disease with portions
of the genome through the use of a high number of Single
Nucleotide Polymorphisms (SNPs) [83]. Amajor study of the
GABRIEL consortium in Europe involved 10,365 patients and
16,110 healthy controls who were where genotyped of 582,892
SNPs. One of the major findings was the identification
of the ORMDL3 (ORM1-like protein 3) and the GSDMB
(Gasdermin-B) genes within 17q21 locus and CDK12 (Cyclin-
dependent kinase 12) as candidate genes for childhood-onset
severe asthma [84]. The same 17q21 locus was also associated
with asthma exacerbations, and treatment response, and
ORMDL3 was proposed as candidate gene [85]. ORMDL3
negatively regulates the expression of IL-2. Considering the
role of IL-2 in the differentiation of TH2 cell subsets, this
effect on IL-2 production could represent a genetic risk for
asthma and autoimmunity [86]. As a major finding of these
projects, asthma onset has been associated with a number
of genes coding for HLA, IL-13, IL-33, thymic stromal
lymphopoietin [TSLP], IL-1 receptor-like 1 [IL-1RL1], ST2,
and the receptor for IL-33. Furthermore RAR-related orphan
receptor A [RORA], SMAD family member 3 [SMAD3],
and GATA3 were identified [87]. CDHR3 gene has also
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Figure 2: From omics technology to personalized medicine. From DNA microarray to Next Generation Sequencing (NGS), system biology
provides for management and data analysis. This path is moving forward to the development of “precision medicine” approaches.
been described in severe asthma in addition to GSDMB, IL-
33, and IL-1RL1. Furthermore, CDHR3 gene expression was
associated with exacerbation in children asthma population
from 2 to 6 years of ages [88, 89].
A study conducted on severe asthma in Italian patients
found a significant association between the SNP rs848 within
the IL-13 gene and severe asthma symptoms [90]. A corre-
lation between HLA-II genes and different asthma pheno-
types has also been described. In particular, HLA-DRB1 is
associated with allergic asthma, HLA-DQB1 with occupa-
tional asthma, and HLA-DPB1 with aspirin-sensitive asthma
[91].
10. Pharmacogenomics of Asthma
One of the most important applications of genomic asso-
ciation studies outcomes for severe asthma is pharmacoge-
nomics. This omics science studies genetic variations influ-
encing treatment response to the most commonly used
asthma therapies. For this reason, several studies have already
been successfully performed. For example, BARGE (Beta-
Adrenergic Response by Genotype) trial showed that patients
with an ARG16 variant of ADRB2 gene had a small decline in
lung function compared to Gly16gly genotype. The response
to the short-acting beta-2 agonist (SABA) therapy has been
correlatedwith amutation in the coding sequence of the beta-
2 adrenoceptor [ADRB2] gene that causes aGlycine/Arginine
substitution at position 16 of the receptor protein (Gly16Arg)
[92]. In line with response to SABA, pharmacogenetic works
on response to long acting beta-2 agonist (LABA) have
addressed the ADRB2 gene but no effect on lung function
was found [93].However, theArg16 variant showed an impact
on LABA in pediatric population [94]. Several GWASs on
inhaled corticosteroids (ICS) response in asthmatic popu-
lation were performed but no clinically significant results
were reported [95, 96]. Although Mosteller and coworkers
[95] did not find any significant genetic markers in their
study, other studies have identified a novel SNP, rs10044254,
associated with both decreased expression of the F-Box and
Leucine Rich Repeat Protein 7 [FBXL7] gene and improved
symptomatic response to ICSs in pediatric subjects [97].
These very interesting findings suggest that there might be a
specific genetic mechanism regulating symptomatic response
to ICSs in children not present in adults.
On the opposite, variations of theGLCCI1 gene, encoding
for glucocorticoid-induced transcript 1 protein, have been
associated with a reduction of pulmonary functions. Unfor-
tunately, these results were not confirmed by other clinical
trials. The rs2872507 SNP, which influences ORMDL3 gene
expression at locus 17q21, may be a possible marker for ICS
treatment response in childhood asthma [98]. The rs2872507
T variant of this gene was found in the SHARP population
and is associated with an improvement in FEV1 in asthmatic
patient on ICS therapy. Many clinical trials investigated the
response to leukotriene modifiers, and, despite a quantity of
candidate gene, only 5-lipoxygenase (ALOX-5), transporter
gene (MRP1), and ATP-binding cassette (ABCC1) trans-
porters were found to be involved in the LTRA response
[98]. Despite the efforts dedicated to the investigation of
genetic variations associated with asthma, so far there is no
evidence of strong association with treatment heterogeneity
of response and no pharmacogenetic marker seems to be able
to reach clinical relevance. Further investigations are there-
fore needed to identify specific genetic variation influencing
treatment response and to provide new distinct asthma phe-
notypes.
11. Transcriptomics
Bigler and collaborators recently performed a whole genome
expression of blood cell in asthma. In this research, 1,693
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genes were differentially expressed in severe asthmatic
patients [99]. Using bronchial epithelium and induced spu-
tum samples, several case/control studies tried to define
the different asthma subtypes through differential expres-
sion of messenger RNA (mRNA). Woodruff and coworkers
identified the two most popular asthma subgroups, “T2-
high” and “T2-low,” through the different expression of IL-
5 and IL-13 transcripts in bronchial biopsies. Furthermore,
epithelial expression of POSTN (periostin), CLCA1 (calcium-
activated chloride channel regulator 1), and SERP1NB2 gene
transcripts may be predictive of a Th2 driven inflammation
[100]. Shikotra et al. found an upregulation of the CEACAM6
(carcinoembryonic antigen related cell adhesion molecule 6)
transcript in bronchial biopsies of asthmatic patients; it was
associated with airway epithelial cells and tissue neutrophils,
showing that theCEACAM6 expression levels could be linked
to a Neutrophilic asthma phenotype [101].
In the past few years, some studies aimed at identifying
a “T2 gene-based discrimination” in induced sputum sam-
ples, which is less invasive than bronchial biopsies [102].
Other studies detected seven gene transcripts [COX-2 (cyclo-
oxygenase-2), ADAM-7 (disintegrin and metalloproteinase
domain-containing protein 7), SLCO1A2 (solute carrier
organic anion transporter family member 1A2), TMEFF2
(transmembrane protein with epidermal growth factor like
and two follistatin like domains 2), TRPM-1 (transient recep-
tor potential cation channel subfamilyMmember 1), and two
unnamed] in bronchial brushing samples with expression
levels that were moderately correlated with submucosal
eosinophils [103].
Severe asthma in adults is characterized by inflammatory
pathways involving mast cells, eosinophils, and group 3
innate lymphoid cells detected in induced sputum, endo-
bronchial, and nasal brushing [104]. Baines et al. identified
transcriptional inflammatory asthma phenotypes (TAPs) by
studying the gene expression profile from induced sputum
of adult stable asthma. Three distinct TAPs groups were
identified: TAP 1 Eosinophilic, TAP2 Neutrophilic, and TAP3
Paucigranulocytic [105]. When the TAP profiles were com-
paredwith gene expression analyses of sputum, a 92%of over-
lap was detected.
MicroRNAs. MicroRNAs (miRNAs) are small noncoding
single RNAs strands that regulate gene expression at the
posttranscriptional level. MiRNAs are involved in all of
the most important cells functions including the control of
inflammatory processes; therefore numerous studies have
been conducted to better understand the involvement of
miRNAs in several diseases. The characterization of miRNAs
and their rolemay represent an important tool for endotyping
the complex asthma phenotype picture, when investigated
in tissues whose collection is less invasive than common
bronchial biopsies and induced sputum, such as peripheral
blood.
MicroRNA expression in the peripheral blood has been
investigated in a small study that compared seven mild
asthmatics and four healthy subjects. This study detected an
underexpression of microRNA 192 when study population
underwent allergen inhalation challenge [106].
The interest in miRNA study as potential source of bio-
markers is increasing. It has been shown in serum a differen-
tial expression of miR-1248 in asthmatic versus nonasthmatic
patients and it has been demonstrated that miR-1248 is
directly involved in the regulation of IL-5 transcript [107].
So far, severity of asthma had a minor impact on miRNA
expression when it was evaluated on nasal biopsies of asthma
patient [108]. However, a recent case-control study that inves-
tigated severe equine asthma identified 11 miRNAs differen-
tially expressed. One of this miRNAs was the MiR-128 [109],
which is part of a regulatory miRNA network and it has been
already shown to be downregulated in bronchial epithelial
cells of asthmatic patients. These results were confirmed by
a significant increase of interleukin-6 (IL-6) and interleukin-
8 (IL-8) that are associated with pathophysiology of asthma
[110].
A preliminary miRNA study has also been performed for
pediatric asthma (12 cases and 6 controls) that showed an
upregulation ofMiRNA-221 andmiRNA-485-3p in asthmatic
patient [111].
12. Epigenomics
Epigenetic mechanisms include DNA methylation, histone
modifications, and noncoding RNAs, and they can control
gene expression acting on DNA structure and subsequent
regulation. The set of nucleic acid methylation modifications
in an organism's genome is known as methylome. Several
genes linked to asthma are regulated by epigenetic mecha-
nism, such as genes involved in T-effector pathways (inter-
feron INF-𝛾, interleukin-4 (IL-4), IL-13, and IL-17), T-regu-
latory pathways (forkheadbox P3 [FoxP3]), and airway in-
flammation (arginase [ARG]) [112].
A study on African American inner-city children identi-
fied 81 differentiallymethylated regions (DMRs) in peripheral
blood mononuclear cells (PBMCs) related to allergic asthma.
Several immune genes were hypomethylated including IL-13,
RUNX3, and TIGIT [113].
Breton’s group in 2011 studied the DNA methylation of
specific genes and investigated biomarkers of airway inflam-
mation.They foundmethylation levelsof severalCpG (regions
with a high frequency of CpG site) loci located in promoter
regions of ARG genes associated with FeNO. This finding
could explain a possible role of DNA methylation in the
regulation of nitric oxide production [114].
An epigenetic association between serum IgE levels and
methylation at different loci using DNA from peripheral
blood leukocytes demonstrated that genes annotated to these
loci encode known eosinophil products.This finding suggests
that methylation differed significantly in isolated eosinophils
from subjects with and without asthma and high IgE levels
[115].
13. Proteomics
The currently available literature provides several examples
of detection of proteins involved in inflammatory mecha-
nisms of asthma; they are commonly profiled using mass
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spectrometry. Proteome analyses research so far has been
conducted in limited sample-size studies on bronchoalveolar
lavage fluid (BALF) [116, 117], bronchial biopsies [118], and
sputum supernatants [119, 120]. A large-scale study stratified
severity of asthma relying on granulocytes inflammatory in
sputum. Patients were divided into different groups: <2% or
>2% eosinophils and<40%or> 40%neutrophils.Microarray
data showed different inflammatory proteins between groups
[118]. The SARP group was able to identify four groups of
asthma from mild-moderate to severe using the protein ex-
pression level of 18 targeted cytokines [121].
Proteomics signatures have been investigated also in bio-
psies of omalizumab responder (OR) versus nonomalizumab
responder (NOR) phenotypes after 36 months of treatment.
Baseline galectin-3 expression was found in OR patients but
not inNOR.Galectin-3 detectionwas related to an improving
of respiratory function in OR and it could be considered as
a potential biomarker of long-term response to omalizumab
[122].
14. Metabolomics
In order to differentiate asthma endotypes, many studies
recently suggested that a measure of metabolic profiles in dif-
ferent samples including exhaled breath, urine, plasma, and
serum may be applied [123]. Nowadays the most attractive
area ofmetabolomics is “breathomics” [124]. It is based on the
use of an electronic nose that recognizes a profile of volatile
organic compounds (VOCs) in exhaled breath and is able to
discriminate asthmatics from healthy controls [125, 126].
One of the studies in the field obtained a fingerprint of
VOCs for asthma atopic patients by employing mass spec-
trometry combined with electronic nose [127].
Another small size study (25 patients) compared the
eNOSE performance to sputum eosinophils and exhaled
nitric oxide (FeNO). The eNOSE was able to discriminate
asthmatics fromhealthy subjects and to predict corticosteroid
response in asthmatics [126]. Furthermore, the fingerprint
identified by the eNOSE correlated with the percentage of
sputum eosinophils [127, 128]. Metabolomics seems to be
a promising tool in identifying asthma endotypes and bio-
markers; however additional studies are needed in order to
enhance the knowledge and obtain a standardized approach.
15. Conclusions
From the conventional definition of asthma to the inclusion
of new contemporary endotypes, science has been making
huge strides in the field of asthma. To date, the endotyping
dichotomy between T2-high and T2-low based on inflamma-
tory and pathophysiology pathways improved asthma man-
agement. Currently, T2-high endotype is better understood
andmost of new biological therapies address T2-high asthma
treatment. Among biological treatments, omalizumab has a
well-documented efficacy, safety, and effectiveness. However,
many studies have been conducted on other drugs targeting
the T2-high pathway and this includesmepolizumab (already
available on themarket) and reslizumab. Both target IL-5 and
their long-term efficacy is now confirmed by many studies.
Benralizumab and dupilumab, addressing as well Th2-high
inflammation, will be available in the near future.
On the other hand, the pathogenesis and pathophysiology
of T2-low endotypes remain so far unclear and treatment
options specifically addressing T2-low pattern are still lack-
ing, except for BT.
Although the knowledge concerning asthmamechanisms
is increasing, biomarkers research needs to be improved, in
order to identifymolecules univocally selective for the appro-
priate therapies and predicting response to treatment. Achiev-
ing that goal is much more needed in the frame of mAbs
sustainability.
A great support could come from the omics technologies.
This is a new way to approach science and data analysis.
Omics technologies are facilitating rapid advance in under-
standing the molecular details of asthma pathogenesis and
pathophysiology. It implies a commercial counterpart both
in pharmaceutical and in biotechnology research, aimed at
offering system biology solutions to drug developers and
diagnostics companies.
Although the interest in omics technologies is increasing,
several limitations still restrict their wide clinical use. Indeed,
none of the above-mentioned omics signatures have been
translated into clinical practice. Large-scale studies and spe-
cific RCTs are necessary in order to find a real clinical utility
and application of omics science as a biomarker and pro-
gnostic factor. For example, a study conducted in a cohort of
194 asthmatic patients identified 6 clinical and pathobiolog-
ical clusters based on blood and induced sputum measures
[129].
From the omics, circulating miRNA deserves a specific
interest. Circulating miRNAs might be a noninvasive bio-
marker useful to diagnose and characterize asthma. Hyper-
link’s team studied the expression of miRNA in the blood
of asthmatic patients compared with nonasthmatic patients.
Their results showed a subset of circulating miRNA (miR-
125b, miR-16, miR-299-5p, miR-126, miR-206, andmiR-133b)
expressed in patients with allergic rhinitis and asthma [130].
The power of the new miRNA’s technology consists in
easy sampling, exposing the patient to the lowest possible
risk and the cheap and reproducible method of quantifying
miRNA blood levels.
The recent Italian register, as well as the European (U-
BIOPRED) and American (SARP) ones, can represent an
excellent source for data and future studies. T2-low endotypes
management represents the most urgent unmet need to be
addressed through the use of these new technologies, which
however provide a formidable support for better under-
standing and treating any asthma type.
We need to consider that real-life applicability of omics
technologies is still far from the levels that could be expected.
In the last two decades we have witnessed an exponen-
tial increase of biological therapies in oncologic fields and
regarding therapies for treatment of rheumatic diseases, solid,
and blood cancer. On the opposite, in asthma area from
2006 to 2017 omalizumab has been the only available mAb.
Recently, both clinical and preclinical researches have literally
exploded.
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Indeed only in recent years have severe asthma therapeu-
tics options expanded their potential thanks to development
of new drugs.
Despite an increasing interest in omics technology, we
need to take into account the fact that none of the omics
signatures mentioned above has been translated into clinical
practice and that it is one of the major limits. For this reason,
development of large-scale studies is urgently needed. Partic-
ularly, specific Randomized Controlled Trials (RCTs) would
be necessary to definitively confirm the clinical relevance
of omics and reinforcing omics role in searching for new
biomarkers and prognostic factors. The need for correctly
selecting the right mAb for the right patient is one of the key
points in severe asthma management.
The challenge in the “omics era” is to translate frombench
to bedside this huge amount of data coming from the above-
mentioned dataset. Translation in clinical practice through
RCT is needed to emphasize omics’ role in precisionmedicine
and to predict response to treatments.
Finally, the study of the interaction between the different
biomarkers will be extremely important for better under-
standing asthma progress and evaluating the possible nega-
tive impact of some therapies. For these purposes, the appli-
cation of mathematical models that gather the interaction
of the different biomarkers will provide a great help, as well
as the application of machine learning approaches that will
help to decide themost successful therapies.These promising
fields seem to be still far from application in the asthma field,
but we are confident they will be widely investigated in the
upcoming years, similarly to other medical fields.
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